Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)

Next Previous
X
Search
Trial Profile

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Tasadenoturev (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Acronyms CAPTIVE; KEYNOTE-192
  • Sponsors DNAtrix

    • Most Recent Events

    • 01 Jun 2023 Primary endpoint (Overall safety) has been met, as per results published in the Nature Medicine.
    • 01 Jun 2023 Primary endpoint (Objective response rate (ORR)) has not been met, as per results published in the Nature Medicine.
    • 01 Jun 2023 Results assessing the combination of intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous pembrolizumab in recurrent glioblastoma, first in a dose-escalation and then in a dose-expansion phase, published in the Nature Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top